Marion E. Frew

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials

Panagiotis Kottaridis, Rosemary E. Gale, Marion E. Frew et al. · Blood · 2001 · 1.5K citations · Full text

Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors

Panagiotis Kottaridis, Rosemary E. Gale, Stephen E. Langabeer et al. · Blood · 2002 · 304 citations · Full text

Aberrant methylation of the negative regulators <i>RASSFIA</i>, <i>SHP‐1</i> and <i>SOCS‐1</i> in myelodysplastic syndromes and acute myeloid leukaemia

Muhammad Farid Johan, David Bowen, Marion E. Frew et al. · British Journal of Haematology · 2005 · 83 citations

CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but not associated withFLT3 internal tandem duplication

David Bowen, Marion E. Frew, Sara Rollinson et al. · Blood · 2003 · 45 citations · Full text